166 related articles for article (PubMed ID: 19896842)
1. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
3. N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Raeppel S; Claridge S; Saavedra O; Gaudette F; Zhan L; Mannion M; Zhou N; Raeppel F; Granger MC; Isakovic L; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman J; Vaisburg A
Bioorg Med Chem Lett; 2009 Mar; 19(5):1323-8. PubMed ID: 19211249
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
7. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
[TBL] [Abstract][Full Text] [Related]
8. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
12. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.
Raeppel S; Gaudette F; Mannion M; Claridge S; Saavedra O; Isakovic L; Déziel R; Beaulieu N; Beaulieu C; Dupont I; Nguyen H; Wang J; Macleod AR; Maroun C; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2010 May; 20(9):2745-9. PubMed ID: 20363625
[TBL] [Abstract][Full Text] [Related]
17. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
[TBL] [Abstract][Full Text] [Related]
18. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
[TBL] [Abstract][Full Text] [Related]
19. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
